Annovis Bio announced completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer’s disease. Topline efficacy data is expected in April. “We are excited to share that we now move from data cleaning to organization and statistical evaluation of data for our Alzheimer’s study, which was completed in February. To clean data this fast is truly a tremendous achievement,” said Cheng Fang, Ph.D., Senior Vice President of Annovis. “The team has been working hard to provide trustworthy data, and we look forward to the topline results as we plan to announce it next month.” The phase II/III AD study was a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap in patients with mild to moderate AD. This was a dose ranging study where patients received either one of three doses of buntanetap – 7.5mg, 15mg, or 30mg – or placebo on top of their standard of care for 12 weeks. Over 700 patients were screened with a total of 353 patients enrolled and 327 patients completed the study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
